Journal: Discover Oncology

Article Title: Spatial transcriptomics of urothelial carcinoma with basal/squamous differentiation identifies Galectin-7 as a specific marker of squamous lineage commitment

doi: 10.1007/s12672-026-04927-z

Figure Lengend Snippet: LGALS7 is selectively expressed in Ba/Sq differentiation and promotes squamous carcinoma cell proliferation. A The H&E image from Fig. B is shown again, with a red box indicating the region analyzed in this figure. Spatial transcriptomic maps display TP63 and LGALS7 expression patterns within the boxed region, corresponding to the UC–Ba/Sq interface. B Cluster-level expression of TP63 and LGALS7. C Immunohistochemistry (IHC) of the cystectomy specimen showing diffuse p63 positivity in both urothelial carcinoma (UC) and Ba/Sq-differentiated tumor components, and selective Galectin-7 expression restricted to Ba/Sq-differentiated tumor nests. Scale bars, 1 mm. D Western blot showing Galectin-7 expression across cancer cell lines (left), and immunofluorescence (IF) of SCaBER cells showing cytoplasmic localization (right). E Proliferation assay of SCaBER cells following LGALS7 knockdown

Article Snippet: It is highly expressed in normal stratified epithelia, and strong Galectin-7 expression has also been observed in benign squamous epithelial lesions such as cholesteatoma [ , ].

Techniques: Expressing, Immunohistochemistry, Western Blot, Immunofluorescence, Proliferation Assay, Knockdown

Journal: Discover Oncology

Article Title: Spatial transcriptomics of urothelial carcinoma with basal/squamous differentiation identifies Galectin-7 as a specific marker of squamous lineage commitment

doi: 10.1007/s12672-026-04927-z

Figure Lengend Snippet: Diagnostic and prognostic value of Galectin-7 in urothelial carcinoma. A Immunohistochemistry (IHC) for p63 and Galectin-7 in UC with Ba/Sq features ( n = 28) and UC without Ba/Sq ( n = 64). B Immunohistochemistry (IHC) of three representative UC with Ba/Sq differentiation cases showing diffuse p63 positivity in both urothelial carcinoma (UC) and Ba/Sq-differentiated tumor components, and selective Galectin-7 expression restricted to Ba/Sq-differentiated tumor nests. Scale bars, 100 μm. C Summary of key clinicopathological parameters associated with Galectin-7 (G7) expression. Detailed clinicopathological data are provided in Supplementary Table 1. Kaplan–Meier analysis of progression-free survival stratified by Galectin-7 expression

Article Snippet: It is highly expressed in normal stratified epithelia, and strong Galectin-7 expression has also been observed in benign squamous epithelial lesions such as cholesteatoma [ , ].

Techniques: Diagnostic Assay, Immunohistochemistry, Expressing

Journal: Discover Oncology

Article Title: Spatial transcriptomics of urothelial carcinoma with basal/squamous differentiation identifies Galectin-7 as a specific marker of squamous lineage commitment

doi: 10.1007/s12672-026-04927-z

Figure Lengend Snippet: LGALS7 is selectively expressed in Ba/Sq differentiation and promotes squamous carcinoma cell proliferation. A The H&E image from Fig. B is shown again, with a red box indicating the region analyzed in this figure. Spatial transcriptomic maps display TP63 and LGALS7 expression patterns within the boxed region, corresponding to the UC–Ba/Sq interface. B Cluster-level expression of TP63 and LGALS7. C Immunohistochemistry (IHC) of the cystectomy specimen showing diffuse p63 positivity in both urothelial carcinoma (UC) and Ba/Sq-differentiated tumor components, and selective Galectin-7 expression restricted to Ba/Sq-differentiated tumor nests. Scale bars, 1 mm. D Western blot showing Galectin-7 expression across cancer cell lines (left), and immunofluorescence (IF) of SCaBER cells showing cytoplasmic localization (right). E Proliferation assay of SCaBER cells following LGALS7 knockdown

Article Snippet: B Immunohistochemistry (IHC) of three representative UC with Ba/Sq differentiation cases showing diffuse p63 positivity in both urothelial carcinoma (UC) and Ba/Sq-differentiated tumor components, and selective Galectin-7 expression restricted to Ba/Sq-differentiated tumor nests.

Techniques: Expressing, Immunohistochemistry, Western Blot, Immunofluorescence, Proliferation Assay, Knockdown

Journal: Discover Oncology

Article Title: Spatial transcriptomics of urothelial carcinoma with basal/squamous differentiation identifies Galectin-7 as a specific marker of squamous lineage commitment

doi: 10.1007/s12672-026-04927-z

Figure Lengend Snippet: Diagnostic and prognostic value of Galectin-7 in urothelial carcinoma. A Immunohistochemistry (IHC) for p63 and Galectin-7 in UC with Ba/Sq features ( n = 28) and UC without Ba/Sq ( n = 64). B Immunohistochemistry (IHC) of three representative UC with Ba/Sq differentiation cases showing diffuse p63 positivity in both urothelial carcinoma (UC) and Ba/Sq-differentiated tumor components, and selective Galectin-7 expression restricted to Ba/Sq-differentiated tumor nests. Scale bars, 100 μm. C Summary of key clinicopathological parameters associated with Galectin-7 (G7) expression. Detailed clinicopathological data are provided in Supplementary Table 1. Kaplan–Meier analysis of progression-free survival stratified by Galectin-7 expression

Article Snippet: B Immunohistochemistry (IHC) of three representative UC with Ba/Sq differentiation cases showing diffuse p63 positivity in both urothelial carcinoma (UC) and Ba/Sq-differentiated tumor components, and selective Galectin-7 expression restricted to Ba/Sq-differentiated tumor nests.

Techniques: Diagnostic Assay, Immunohistochemistry, Expressing